JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo

Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells

(2014) A. M. Cook et al.   BLOOD

The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells

(2014) C. I. Kobayashi et al.   BLOOD

Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation

(2013) E. Keil et al.   BLOOD

Autocrine TNF-  production supports CML stem and progenitor cell survival and enhances their proliferation

(2013) P. Gallipoli et al.   BLOOD

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

(2013) Min Chen et al.   JNCI-Journal of the National Cancer Institute

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

(2013) T Zhou et al.   LEUKEMIA

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

(2013) Concetta Quintarelli et al.   LEUKEMIA RESEARCH

Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans

(2013) Sung O. Park et al.   PLoS One

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice

(2012) C. Walz et al.   BLOOD

Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML

(2012) Florian H. Heidel et al.   Cell Stem Cell

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

(2012) Oliver Hantschel et al.   Nature Chemical Biology

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

(2011) S. Chu et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

(2011) W. Warsch et al.   BLOOD

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

(2011) E. A. Nelson et al.   BLOOD

Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia

(2011) Jorge Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

(2011) Christian Hurtz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors

(2011) E Traer et al.   LEUKEMIA

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML

(2011) Rajesh R. Nair et al.   LEUKEMIA RESEARCH

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib

(2010) M. Sobrinho-Simoes et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans

(2010) A. D. Shilling et al.   DRUG METABOLISM AND DISPOSITION

Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia

(2010) Andrea Hoelbl et al.   EMBO Molecular Medicine

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

(2010) D K Hiwase et al.   LEUKEMIA

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

(2010) A Samanta et al.   LEUKEMIA

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

(2010) D M Ross et al.   LEUKEMIA

ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling

(2009) A. D. Wood et al.   BLOOD

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia

(2008) Y Hu et al.   LEUKEMIA